Medpace Holdings, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter earnings report. Medpace is a global clinical research organization providing Phase I–IV development services, with approximately 5,900 employees across 42 countries.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 | Change |
|---|---|---|---|
| Revenue | $1,885.8 million | $1,460.0 million | +29.2% |
| Operating income | $336.8 million | $278.7 million | +20.9% |
| Operating margin | 17.9% | 19.1% | Down 1.2 percentage points |
| Net income | $282.8 million | $245.4 million | +15.3% |
| Diluted EPS | $8.88 | $7.28 | +22.0% |
| Operating cash flow | $433.4 million | $388.1 million | +11.7% |
- Net margin was approximately 15.0%, compared with 16.8% in 2022. Direct costs increased 32.5%, faster than revenue, including a 46.8% increase in reimbursed out-of-pocket expenses and higher personnel costs.
- Cash and cash equivalents were $245.4 million at year-end, versus $28.3 million a year earlier. Cash flow from investing was an outflow of $34.6 million, primarily for property and equipment; financing cash flow was an outflow of $182.6 million.
- No debt was outstanding at year-end; $150.0 million was available under the revolving credit facility. The company reported $164.5 million of operating lease liabilities.
- Net new business awards were $2,356.7 million, up from $1,829.5 million. Backlog rose 20.2% to $2,813.0 million; management expected approximately $1,520–$1,540 million of that backlog to convert to revenue in 2024.
- The effective tax rate increased to 15.8% from 13.3%. Management attributed the increase primarily to higher pre-tax income, increased uncertain tax positions, and lower excess tax benefits from share-based compensation, partly offset by increased FDII benefits.
Material changes and notable items
- Revenue growth was broad-based, led particularly by Metabolic, Oncology, AVAI, and other therapeutic areas. Metabolic revenue increased to $376.8 million from $244.7 million; Oncology revenue increased to $587.1 million from $467.8 million.
- Operating income grew more slowly than revenue, and operating margin declined. SG&A increased 22.8%, mainly due to personnel costs supporting growth.
- Share repurchases totaled $144.0 million in 2023 for 781,068 shares; $308.8 million remained authorized at year-end. No repurchases occurred in the fourth quarter. The company has not paid dividends and does not currently plan to do so.
- Government assistance reduced expenses by $15.5 million in 2023. The company recorded a $5.2 million liability for interest and penalties associated with uncertain tax positions.
- Revenue recognition relies on estimates of total contract costs and progress toward completion. Deloitte identified revenue recognition for clinical research contracts as a critical audit matter, citing the judgment involved in estimating costs to complete.
Outlook, risks, and contingencies
- Management stated that existing cash, operating cash flow, and available borrowing capacity should be sufficient for near- and longer-term needs, while noting there is no assurance that future cash flows or borrowing availability will meet all needs.
- The filing provides no formal full-year 2024 revenue or earnings guidance; the $1.52–$1.54 billion conversion estimate relates to year-end backlog, not total expected revenue.
- Key risks include cancellations or delays of customer projects, uncertain backlog conversion, customer funding constraints, fixed-fee contract cost overruns, and difficulty obtaining timely approval for scope changes. Contracts are generally terminable by customers, typically on 30 days’ notice.
- Small and mid-sized biopharmaceutical companies generated 78% and 18% of 2023 revenue, respectively. The top ten customers represented approximately 29.5% of revenue; no single customer accounted for 10% or more.
- Additional risks include competition and pricing pressure, hiring and retention, patient enrollment, regulatory and clinical-trial compliance, privacy and cybersecurity, foreign exchange, inflation, and geopolitical disruption. A 10% adverse foreign-exchange movement would have reduced 2023 pre-tax income by an estimated $17.2 million.
- Management said pending legal matters were not reasonably likely to have a material adverse effect on the consolidated financial statements. The filing reports $17.2 million of minimum purchase commitments expiring at various times through 2029.
- Related-party transactions include headquarters leases with entities owned by the CEO and family members, clinical services for companies with executive or employee affiliations, and $2.0 million of executive travel expenses involving a CEO-controlled aviation company. The CEO controlled approximately 20.8% of outstanding shares as of year-end.
Key facts for investors to verify
- Whether backlog converts to revenue as expected, and how cancellations, project timing, and scope changes affect conversion.
- Whether revenue growth can translate into stable or improving operating margins as labor, reimbursed expenses, and other costs rise.
- The quality and sustainability of operating cash flow, including the contribution from higher advanced billings and accrued expenses.
- Customer funding and concentration exposure, particularly given the large share of revenue from small and mid-sized biopharma companies.
- The terms, governance, and financial impact of related-party leases and other affiliated transactions, along with the remaining share-repurchase authorization.
- Potential tax, foreign-exchange, cybersecurity, and regulatory developments; the filing reports effective financial reporting controls and unqualified audit opinions.